SUBSCRIBERS
Allergan bets on rising popularity of botox for men
Move is part of firm's strategy to go after smaller markets in traditional pharmaceutical industry
Published Thu, Jun 18, 2015 · 09:50 PM
New York
FINE lines. Double chins. Sagging skin. Allergan Plc is betting that these byproducts of ageing are becoming an obsession for men.
After completing a deal valued at US$70.5 billion to buy the maker of Botox injections, Allergan announced on Wednesday that it would pay US$2.1 billion for Kythera Biopharmaceuticals Inc. The latest transaction gives the company an experimental drug for male-pattern baldness and an injection that is the only regulator-approved non-surgical treatment for a double chin - a condition that Kythera has said bothers men as much as women.
Share with us your feedback on BT's products and services
